ACAMOL FOCUS

Country: Israel

Language: English

Source: Ministry of Health

Buy It Now

Active ingredient:

ACETYLSALICYLIC ACID; CAFFEINE; PARACETAMOL

Available from:

TEVA ISRAEL LTD

ATC code:

N02BE01

Pharmaceutical form:

CAPLETS

Composition:

ACETYLSALICYLIC ACID 250 MG; PARACETAMOL 250 MG; CAFFEINE 65 MG

Administration route:

PER OS

Prescription type:

Not required

Manufactured by:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

Therapeutic group:

PARACETAMOL

Therapeutic area:

PARACETAMOL

Therapeutic indications:

For temporary relief of the pain of headache, mild to moderate pain associated with migraine headache, pain of menstrual descomfort and pain accompanied by fever.

Authorization date:

2014-07-31

Patient Information leaflet

                                .ءاودلا قحس وأ رطش عنم
ُ
ي
.غضملا /قحسلا/رطشلا لوح تامولعم رفوتت
لا
.ءاودلا لوانت دعب ةقيقد 15-30 للاخ
ءاقلتسلاا عنم
ُ
ي
لوانت عنم
ُ
ي .نييفاكو لوماتيساراپ ،)نيرپسأ(
كيليسيلاسلا ضمح ىلع سوكوف لوماكأ
تلاوسبح يوتحت
تا
ّ
بكرم وأ تاب
ّ
كرملا هذه ىلع يوتحت دق يتلا ىرخلأا
ةيودلأا لوانت عنم
ُ
يو اهب ىصوملا ةعرجلا نم رثكأ
للاخ )باهتللال ةداضملا ةيديوريتسلالا
ةيودلأا) ةعفترملا ةرارحلا وأ باهتللاا
،مللأا جلاعل لمعتست ىرخأ
.سوكوف لوماكأ لامعتسا
.موصلا للاخ ةيودلأا هذه نم )هب ىصوملا
دودح يف( ةعفترم ةعرج لوانت نع عانتملاا
بجي
ىلإ ا
ً
روف ه
ّ
جوتف أطخلا قيرط نع ءاودلا نم ةي
ّ
مك علاتباب لفط ماق اذإ وأ ةطرفم ةعرج
تلوانت اذإ
.كعم ءاودلا ةبلع رضحأو ،ىفشتسملا يف
ئراوطلا ةفرغ ىلإ وأ بيبطلا
لباق ريغ ررض لوصحل ةلمتحملا رطاخملا
ءوض ىلع ،ةيمهلأا غلاب يروفلا يبطلا
جلاعلا ربتعي
لاأ ةطرفملا ةعرجلا نأش نم هنلأ
،ضارعلأا روهظ رظتنت لا .لوماتيساراپلا
ببسب دبكلل حلاصلإل
.اهتظحلام ناكملإاب ضارعأ ةيأ ةيادبلا
يف ببست
:نوكت دق اهنإف ،ةطرفملا ةعرجلا ضارعأ
ترهظ اذإ
•
،ةرارحلا عافترا ،سفنتلا طرف ،ق
ّ
رعت ،ممص ،نينذلأا يف نينط ،راود
:(نيرپسأ) كيليسيلاسلا ضمحل ةبسنلاب
.يس
ّ
فنت لشف وأ (مدلا ق
ّ
فدت) ةيومدلا ةرودلا رايهنا ،ةحارلا
مادعنا وأ (ةلبلب) ك
ّ
بلت ،سأرلا يف
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                Acetylsalicylic Acid, Paracetamol & Caffeine Caplets 14. 2. 2005, RH
":
ע עבקנ הז ןולע טמרופ
"
לע רשואו קדבנ ונכותו תואירבה דרשמ י
ודי
"
A
CETYLSALICYLIC
A
CID
,
P
ARACETAMOL
&
C
AFFEINE
CAPLETS
Composition
Each plain biconvex caplet contains:
_ _
_Active Ingredient _
Acetylsalicylic acid
250 mg
Paracetamol
250 mg
Caffeine
65 mg
_ _
_Other Ingredients _
Microcrystalline
cellulose,
crospovidone,
stearic
acid,
silicon
dioxide,
color
[hydroxypropyl methylcellulose, FD&C red #40, FD&C yellow #6,
polyethylene glycol
400, titanium dioxide, polysorbate 80].
Mechanism of Action
This
preparation
provides
a
powerful,
quick-acting
analgesia.
The
synergistic
combination
of
acetylsalicylic
acid,
paracetamol
and
caffeine
produces
greater
analgesia than that produced by each component alone. Administered
alone, this
preparation
relieves
pain
associated
with
migraine
headache,
as
well
as
pain
associated with other conditions (see Indications).
Indications
For temporary relief of the pain of headache, mild to moderate pain
associated with
migraine headache, pain due to sinusitis or colds, muscular aches,
pain of menstrual
discomfort, toothaches and minor arthritis pain and pain accompanied
by fever.
Contraindications
•
Known hypersensitivity to any ingredient of the preparation.
•
Hemophilia
•
Bleeding ulcers
•
Pregnancy and lactation (see Warnings).
•
Hemorrhagic states
•
Hypersensitivity
to
other
nonsteroidal
anti-inflammatory
agents
which
inhibit
prostaglandin synthesis (see also Warnings).
•
Newborn or premature infants
•
Asthma in combination with nasal polyps
•
In patients that suffered in the past from the following side effects
after taking an
analgesic or a fever lowering medicine: urticaria, swelling of the
face, asthma,
shock.
•
In children and adolescents below 20 years of age, for diseases
accompanied by
fever, such as chiken pox or flu.
Warnings
_For Acetylsalicylic Acid _
Acetylsalicylic acid may precipitate bronchospasm and induce asthmatic
attack
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Arabic 04-08-2022
Patient Information leaflet Patient Information leaflet Hebrew 04-08-2022

View documents history